Asherman’s Syndrome – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

 

Asherman's syndrome, also known as intrauterine adhesions, arises due to trauma to the basal layer of the endometrium, typically occurring after the curettage of the endometrium following a recent pregnancy. These adhesions can range from minor to severe and impact both menstrual function and fertility. Asherman's syndrome primarily manifests after dilation and curettage procedures performed for elective termination of pregnancy, missed or incomplete miscarriage, or to treat a retained placenta after delivery. It may occur with or without hemorrhage following delivery or elective termination of pregnancy. In less frequent cases, it may develop after dilation and curettage for non-obstetrical reasons such as excessive bleeding, endometrial cancer sampling, or removal of endometrial polyps. Additionally, it can arise following surgical removal of uterine fibroids. The syndrome occurs when trauma or removal of the basal layer of the endometrium in opposing areas within the uterine cavity occurs. This injury triggers an inflammatory response that leads to adhesive bands forming from one side of the cavity to the other. Notably, abnormalities in placentation, where the placental tissue extends below the basal layer of the endometrium, significantly increase the risk of developing Asherman's syndrome. The extent of the adhesions determines the severity of the condition, categorized as mild, moderate, or severe. These adhesions can be thin or thick, located sporadically or in a confluent manner. It is important to note that the adhesive bands are typically avascular, which is crucial when discussing treatment options. The American Fertility Society classifies the severity of Asherman's syndrome into three stages:

1. Mild disease: characterized by a few filmy adhesions affecting less than one-third of the uterine cavity, with normal menstrual cycles or hypomenorrhea
2. Moderate disease: marked by filmy and dense adhesions involving one-third to two-thirds of the cavity, resulting in hypomenorrhea
3. Severe disease: characterized by dense adhesions affecting more than two-thirds of the cavity, leading to amenorrhea

Patients with moderate to severe disease have lower chances of conceiving and delivering a healthy pregnancy. However, surgical intervention may improve fertility outcomes if the uterine cavity can be reconstructed and menstrual cycles resume. It is important to note that even after repeated surgeries, restoring a normal endometrial lining may be delayed or not occur at all.

• Asherman's syndrome can occur in 31% of women after the initial hysteroscopic resection of leiomyoma (uterine fibroids), and the incidence can increase up to 46% after a second hysteroscopic resection.

Thelansis’s “Asherman’s Syndrome Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Asherman’s Syndrome treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

KOLs insights of Asherman’s Syndrome across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.

Asherman’s Syndrome Market Forecast Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.

Thelansis Competitive Intelligence (CI) practice has been established based on a deep understanding of the pharma/biotech business environment to provide an optimized support system to all levels of the decision-making process. It enables business leaders in forward-thinking and proactive decision-making. Thelansis supports scientific and commercial teams in seamless CI support by creating an AI/ ML-based technology-driven platform that manages the data flow from primary and secondary sources.

Read more: Asherman’s Syndrome – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033